Dr. Wei Li
Dr. Wei Li has been named the Knights Templar Eye Foundation Presidential Chair. He joined Baylor in July 2020 with tenure as professor of ophthalmology.
Before his tenure at Baylor, Li was a tenured professor at the Bascom Palmer Eye Institute at the University of Miami. He received his bachelor’s degree and Master of Science in pharmaceutical science and pharmacology, respectively, from Zhejiang University in China before earning his Ph.D. in pharmacology from the University of Nebraska Medical Center.
His research focuses on diabetic retinopathy, age-related macular degeneration and retinopathy of prematurity. His most significant achievement so far is the discovery of secretogranin III (Scg3) as a disease-selective angiogenic factor for next-generation disease-targeting anti-angiogenesis therapy of ocular diseases. He is the inventor of “ligandomics,” an innovative technology that led to the discovery of Scg3 as a therapeutic target.
Li is the co-founder and president of two biotech companies, Everglades Biopharma, LLC and LigandomicsRx, LLC.